Trials / Terminated
TerminatedNCT01420861
GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer
Open Label Study of the Effect of GTx-758 on Serum PSA and Free Testosterone Levels in Men With Castration Resistant Prostate Cancer and Maintained on Androgen Deprivation Therapy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- GTx · Industry
- Sex
- Male
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the effect of GTx-758 on Serum Prostate-specific antigen (PSA) levels in men with castrate resistant prostate cancer who are maintained on androgen deprivation therapy (Serum PSA response and Serum PSA progression)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GTx-758 | two GTx 758 tablets per day |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2011-08-22
- Last updated
- 2023-10-06
- Results posted
- 2023-10-06
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01420861. Inclusion in this directory is not an endorsement.